Clinical Trial: Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Efficacy And Safety Of CX516 (900 Mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-Week Study.

Brief Summary: Glutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 enhances brain activity by specifically targeting remaining glutamate receptors in the affected portions of the brain. This study will test the safety and efficacy of CX516 in the symptomatic treatment of participants with mild cognitive impairment.

Detailed Summary:
Sponsor: RespireRx

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: RespireRx

Dates:
Date Received: June 26, 2002
Date Started: April 2002
Date Completion: March 2003
Last Updated: June 23, 2005
Last Verified: February 2005